Mabwell appoints Executive Director Hua Jun as new authorised representative

Bulletin Express06-18

Mabwell (Shanghai) Bioscience Co., Ltd. announced that, effective 18 June 2026, Executive Director Mr. Hua Jun has been appointed as an authorised representative of the company under Rule 3.05 of the Hong Kong Listing Rules.

Mr. Hu Huiguo has simultaneously ceased to serve in this role. Following the change, Mabwell’s two authorised representatives are Mr. Hua Jun and Ms. Leung Kwan Wai.

The board currently comprises five executive directors—Mr. Tang Chunshan, Dr. Liu Datao (Chairman), Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun—alongside four independent non-executive directors: Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang.

The announcement was issued in Shanghai, PRC, and signed by Chairman and Executive Director Dr. Liu Datao on 18 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment